European Union: Food, Drugs, Healthcare, Life Sciences

This month, at the Unified Patent Court (UPC), the Düsseldorf Local Division’s dismissal of Align Technology’s provisional measures application against Angelalign reinforces the applicant’s evidential...

June 2026 – In case Kfv.VI.37.810/2025/27, the Hungarian Supreme Court (the “Supreme Court”) reviewed an administrative dispute concerning the marketing authorisation of a generic medicinal product.

Recent U.S. case law is reshaping the risks around skinny labelling strategies for generics. What was once seen as a safe regulatory pathway now raises new concerns about infringement

Effective service date for an unrepresented defendant who did not yet make an appearance in court is calculated under R. 271.6.b RoP, subject to the “unless” conditions of that rule.

Gérard Haas et son équipe ont compilé les actualités juridiques numériques les plus marquantes de la semaine, couvrant les alertes d'Anthropic sur l'auto-amélioration récursive de l'IA, les nouvelles sanctions de la DGCCRF contre SHEIN, les risques liés aux chatbots d'intimité, les inquiétudes autour de Doctolib et des données de santé, ainsi que la nouvelle stratégie open source européenne.

Healthcare services around the world are coming under increasing pressure as lengthening life expectancies and aging populations drive patient demand ever higher.

A value-in-dispute determination is a procedural decision governed by R. 220.2 and R. 220.3 RoP, even when included in the operative part of a final decision.

The Netherlands is poised to dramatically expand its foreign direct investment screening regime by adding six highly sensitive technology categories—including biotechnology, artificial intelligence, and nanotechnology...

When assessing the requirement for a procedural security, namely the question whether the Claimant has “sufficient means” to compensate the Defendant for the legal costs incurred in the proceedings, only the financial situation of the Claimant should be taken into consideration, but not the financial situation of the holding company behind the Claimant.